Kanamycin Sulfate
(Synonyms: 硫酸卡那霉素; Kanamycin A sulfate) 目录号 : GC12269
An antibiotic used in molecular biology
Cas No.:25389-94-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Biological Activity: ≥750u/mg
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Animal experiment: |
Sixty-six male Sprague-Dawley rats (initial body weight 125-150 g, 5-6 weeks old) have free access to water and a regular diet, and are allowed 1 week of acclimation before the first treatment. The animals are divided randomly into one control group and seven experimental groups. Control group rats (n=10) are injected subcutaneously with an equal volume of vehicle (0.9% saline) for 10 days as those in the groups of kanamycin treatment, but without kanamycin. The experimental groups (n=56, 8 for each group: 1, 7, 14, 28, 56, 70 and 140 days after kanamycin administration, respectively) receive 500 mg of kanamycin sulfate/kg/day by subcutaneous injection for 10 days. The animal body weight is monitored every day and the injection dosage of kanamycin is adjusted accordingly. Auditory thresholds are tested by ABR. The tests are taken twice for each animal, first prior to the beginning of administration and then at different observing time points after kanamycin treatment. Details for the ABR measurement is described elsewhere. |
|
References: [1]. Fan GR, et al. Reversible neurotoxicity of kanamycin on dorsal cochlear nucleus. Brain Res. 2013 Jan 17. pii: S0006-8993(13)00068-1. |
|
Kanamycin sulfate is an aminoglycoside bacteriocidal antibiotic which acts by binding to the bacterial 30S ribosomes.
Kanamycin sulfate at the concentration above 0.0025% has a significant inhibition on the growth of B. bifidum and has no influence on the other four probiotics at incubation 12 h or 24 h. The optimum selective concentration of kanamycin sulfate in MRS media is 0.005% for selective enumeration of B.bifidum[3]
The neurons damage of the DCN caused by kanamycin (500 mg/kg/day) is reversible and autophagy is upregulated in the neurotoxic course of kanamycin on DCN through JNK1-mediated phosphorylation of Bcl-2 pathway in rats. The serum BUN and Cr levels are both increased at the 1st day after the period of kanamycin administration. The neurons expressing LC3 are increased at 1, 7 and 14 days after kanamycin administration in comparison to the control group. Kanamycin treatment results in the increase of autophagy in a time-dependent manner[1]. Kanamycin sulfate (5 mg/kg) and sodium ampicillin (10 mg/kg) administered intramuscularly (i.m.) separately, and then together, to five pony mares, and the ampicillin concentration exceeds 5 mg/mL in inflamed synovial fluid for some 2.5 h after injection, and kanamycin sulfate concentration exceeds 2 mg/mL for 7 h in the pony[2].
Kanamycin sulfate是一种氨基糖苷类杀菌抗生素，通过结合到细菌30S核糖体发挥作用。 在培养12小时或24小时时，0.0025%以上的Kanamycin sulfate对B. bifidum的生长有显著的抑制作用，并且对其他四种益生菌没有影响。在MRS培养基中，Kanamycin sulfate的最佳选择浓度为0.005%，用于选择性枚举B.bifidum[3]。 大鼠的DCN神经元受到kanamycin (500mg/kg/day)损害是可逆的，并且在kanamycin对DCN的神经毒性过程中，自噬通过JNK1介导的Bcl-2途径磷酸化上调。在kanamycin给药后的第1天，血清BUN和Cr水平均增加。与对照组相比，kanamycin给药后1、7和14天表达LC3的神经元增加。kanamycin治疗导致自噬的时间依赖性增加[1]。将Kanamycin sulfate（5mg/kg）和氨苄青霉素钠（10mg/kg）分别通过肌肉注射（i.m.）给予五匹小马，然后一起给予，青霉素钠浓度在注射后的炎症滑液中超过5mg/mL，而Kanamycin sulfate的浓度在小马体内超过2mg/mL持续7小时[2]。
Reference:
[1]. Fan GR, et al. Reversible neurotoxicity of kanamycin on dorsal cochlear nucleus. Brain Res. 2013 Jan 17. pii: S0006-8993(13)00068-1.
[2]. Mohamed el SW, et al. Tongue actinomycetoma due to Actinomadura madurae: a rare clinical presentation. J Oral Maxillofac Surg. 2012 Nov;70(11):e622-4.
[3]. Guo WS, et al. Effect of Kanamycin Sulfate and Gentamicin on Growth of Probiotics. Advanced Materials Research,2011, 366, 490-493.
[4]. Firth EC, et al. Effect of induced synovial inflammation on pharmacokinetics and synovial concentration of sodium ampicillin and kanamycin sulfate after systemic administration in ponies. J Vet Pharmacol Ther. 1988 Mar;11(1):56-62.
| Cas No. | 25389-94-0 | SDF | |
| 别名 | 硫酸卡那霉素; Kanamycin A sulfate | ||
| 化学名 | 2-(aminomethyl)-6-[4,6-diamino-3-[4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol;sulfuric acid | ||
| Canonical SMILES | C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)O)O)OC3C(C(C(C(O3)CO)O)N)O)N.OS(=O)(=O)O | ||
| 分子式 | C18H36N4O11.H2SO4 | 分子量 | 582.58 |
| 溶解度 | ≥ 29.129mg/mL in Water | 储存条件 | Store at 2-8°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7165 mL | 8.5825 mL | 17.165 mL |
| 5 mM | 0.3433 mL | 1.7165 mL | 3.433 mL |
| 10 mM | 0.1717 mL | 0.8583 mL | 1.7165 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
An edible Kanamycin Sulfate cross-linked cellulose active against multiple pathogenic bacteria
Int J Biol Macromol 2022 Jan 1;194:435-444.34801585 10.1016/j.ijbiomac.2021.11.085
In this work, an edible cellulose-based antibacterial material was prepared by cross-linking 伪-cellulose and Kanamycin Sulfate via glutaraldehyde to form kanamycin sulfate-glutaraldehyde-cellulose. Fourier transform infrared spectroscopy, X-ray photoelectron spectroscopy and X-ray diffraction results indicated that the Kanamycin Sulfate molecule was cross-linked with the molecular chain of cellulose. The optimal mass ratio of Kanamycin Sulfate to 伪-cellulose was 1:100 and the degree of substitution reached 1.11%. The optimal kanamycin sulfate-glutaraldehyde-cellulose material showed an excellent inhabitation against both Gram-positive and Gram-negative bacteria. Meantime, the optimal kanamycin sulfate-glutaraldehyde-cellulose had a marked resistance to gastric acid and had low cell cytotoxicity. To promote the application of the kanamycin sulfate-glutaraldehyde-cellulose material, the porous microspheres were prepared via the sol-gel method. The particle size of the homogeneous porous microspheres is mainly distributed between 1.5 and 2.0 渭m. Therefore, the kanamycin sulfate-glutaraldehyde-cellulose described herein is a potential edible, eco-friendly, potent, stable, inexpensive, and antibacterial carrier material for delivering drugs, proteins, or vaccines.
Efficacy of Switching from Kanamycin Sulfate to Rifaximin in Patients with Hepatic Cirrhosis
Intern Med 2021 May 15;60(10):1501-1507.33361677 PMC8188012
Objective This study evaluated the efficacy associated with switching to rifaximin in patients with hepatic cirrhosis receiving Kanamycin Sulfate for the treatment of hepatic encephalopathy and hyperammonemia. Methods We included 37 patients who switched from Kanamycin Sulfate to rifaximin at our institution from January 2017 to December 2018. The onset of hepatic encephalopathy and changes in blood ammonia values during a six-month period were retrospectively evaluated. Results There were 4 (11%) patients with hepatic encephalopathy at the time of switching from Kanamycin Sulfate to rifaximin. The cumulative incidence of hepatic encephalopathy was 3% and 16% at 3 and 6 months later, respectively. The blood ammonia levels at the time of switching to rifaximin and at 3 and 6 months later were 94 (range, 20-243) 渭g/dL, 95 (range, 33-176) 渭g/dL, and 81 (range, 32-209) 渭g/dL, respectively, and no significant changes were observed. However, in the 11 patients receiving an oral dose of <1,500 mg/day of Kanamycin Sulfate, the blood ammonia levels at the time of switching and at 3 and 6 months later were 136 (range, 35-243) 渭g/dL, 95 (range, 33-150) 渭g/dL, and 63 (range, 43-124) 渭g/dL, respectively. Furthermore, the blood ammonia levels significantly decreased at the time of the switching to rifaximin and at three and six months later (p=0.043 and p=0.011, respectively). Conclusion Switching to rifaximin in hepatic cirrhosis patients receiving Kanamycin Sulfate to treat hepatic encephalopathy and hyperammonemia showed effects that were equivalent to or greater than the original therapy, thereby demonstrating the clinical efficacy.
Carbon dots derived from Kanamycin Sulfate with antibacterial activity and selectivity for Cr6+ detection
Analyst 2021 Mar 21;146(6):1965-1972.33496685 10.1039/d0an02352c
Among antibacterial nanomaterials, carbon dots (CDs) have attracted much attention because of their unique physical and chemical properties and good biosafety. In this study, Kanamycin Sulfate (Kan), a broad-spectrum antibiotic, was used to synthesize novel carbon dots (CDs-Kan) by a one-step hydrothermal method. CDs-Kan showed good inhibitory effects on Gram-negative Escherichia coli and Gram-positive Staphylococcus aureus. Further, scanning electron microscopy revealed that treatment with CDs-Kan and Kan resulted in the same phenomena. In particular, the morphologies of S. aureus cells treated with CDs-Kan and Kan became smaller and irregular, whereas the surfaces of E. coli cells protruded and formed vesicles. These results indicated that CDs-Kan was shown to retain the good antibacterial activity of Kan as well as its main bactericidal functional groups, namely, the amino sugar and amino cyclic alcohol, We refer to this phenomenon as the "preservation property". We also found that CDs-Kan has good biocompatibility and nontoxic properties. Moreover, CDs-Kan was successfully applied to the biological imaging of fungi and plant cells. In addition, CDs-Kan could be used as a fluorescent probe for the quick, sensitive, and selective detection of Cr6+. Therefore, CDs-Kan not only retained the good bacteriostatic properties of Kan but also expanded its application in bioimaging and biosensors.
[Research progress of acute kanamycin sulfate-induced deafness in guinea pig]
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2012 May;26(10):478-80.22870728
To present a summary of current knowledge regarding acute kanamycin sulfate-induced deafness in guinea pig, by reviewing the published literature. Animal model of acute deafness induced by a single dose of Kanamycin Sulfate in combination with ethacrynic acid or furosemide in guinea pig was usually used to investigate the mechanism of cochlear cell degeneration. There were different time sequences of cell degeneration of spiral ganglion cell and hair cell in different studies. The findings may result from different doses, order of two drugs administration or time point chosen. There remains scope for further research in chronic kanamycin-induced deafness, which more replicates the type of exposure to people than acute deafness.
Ototoxicity of Kanamycin Sulfate and the barriers in the inner ear
Otolaryngol Head Neck Surg 1981 Nov-Dec;89(6):1013-8.6801580 10.1177/019459988108900626
The effect of Kanamycin Sulfate administered by three routes on the function of the stria vascularis was monitored electrophysiologically in guinea pigs. The three routes were intramuscular injection, perilymphatic perfusion, or endolymphatic perfusion. Neither systemic administration of 500 mg/kg of body weight per day for 7 to 12 days nor perilymphatic perfusion of 10(-3) M kanamycin affected the endocochlear dc potential (EP). However, with perfusion of kanamycin 10(-3) M in the endolymphatic space, the EP declined severely. Moreover, the decline in the EP was greater with higher concentrations of kanamycin in the endolymphatic perfusate. Furosemide given by each of the three routes produced an approximately equal decrease in the EP. The effects of kanamycin on the cells of the stria vascularis and the evidence for the perilymphatic-endolymphatic and blood-cochlear barriers are discussed.